Download PDF
Synlett 2009(3): 500-504  
DOI: 10.1055/s-0028-1087547
LETTER
© Georg Thieme Verlag Stuttgart ˙ New York

One-Pot Van Leusen Synthesis of 4,5-Disubstituted Oxazoles in Ionic Liquids

Bo Wu, Jun Wen, Ji Zhang, Jing Li, Yong-Zhe Xiang, Xiao-Qi Yu*
Key Laboratory of Green Chemistry & Technology, Ministry of Education, College of Chemistry, Sichuan University, Chengdu, Sichuan 610064, P. R. of China
Fax: +86(28)85415886; e-Mail: xqyu@scu.edu.cn;
Further Information

Publication History

Received 8 October 2008
Publication Date:
21 January 2009 (online)

    Permissions and Reprints All articles of this category

Abstract

An efficient and mild protocol for the preparation of 4,5-disubstituted oxazoles through an improved one-pot van Leusen oxazole synthesis in ionic liquids is described. The oxazole products were prepared from tosylmethyl isocyanide (TosMIC), aliphatic halides and various aldehydes in high yields. The recovered ionic liquids could be reused as solvent for six runs without significant loss of yields.

Key words

ionic liquids - van Leusen oxazole synthesis - tosyl­methyl isocyanide - halides - aldehydes

    References and Notes

  • 1a Wipf P. Chem. Rev.  1995,  95:  2115 
    Google Scholar
  • 1b Janvier P. Sun X. Bienayme H. Zhu J. J. Am Chem. Soc.  2002,  124:  2560 
    Google Scholar
  • 1c Ikemoto N. Miller RA. Fleitz FJ. Liu J. Petrillo DE. Leone JF. Laquidara J. Marcune B. Karady S. Armstrong JD. Volante RP. Tetrahedron Lett.  2005,  46:  1867 
    Google Scholar
  • 2a Turchi IJ. Dewar MJS. Chem. Rev.  1975,  75:  389 
    Google Scholar
  • 2b Wasserman HH. McCarthy KE. Prowse KS. Chem. Rev.  1986,  86:  845 
    Google Scholar
  • 2c Yeh VSC. Tetrahedron  2004,  60:  11995 
    Google Scholar
  • 2d Martin R. Cuenca A. Buchwald SL. Org. Lett.  2007,  9:  5521 
    Google Scholar
  • 2e Herrera A. Martinez-Alvarez R. Ramiro P. Molero D. Almy J. J. Org. Chem.  2006,  71:  3026 
    Google Scholar
  • 2f Davies JR. Kane PD. Moody CJ. Tetrahedron  2004,  60:  3967 
    Google Scholar
  • 3a Brahma S. Ray JK. J. Heterocycl. Chem.  2008,  45:  311 
    Google Scholar
  • 3b Li B. Buzon RA. Zhang ZJ. Org. Process Res. Dev.  2007,  11:  951 
    Google Scholar
  • 3c Baumann M. Baxendale IR. Ley SV. Smith CD. Tranmer GK. Org. Lett.  2006,  8:  5231 
    Google Scholar
  • 3d Miller RA. Smith RM. Marcune B. J. Org. Chem.  2005,  70:  9074 
    Google Scholar
  • 3e Davies JR. Kane PD. Moody CJ. Tetrahedron  2004,  60:  3967 
    Google Scholar
  • 3f Xia Q. Ganem B. Synthesis  2002,  1969 
    Google Scholar
  • 3g Ohba M. Kubo H. Seto S. Fujii T. Ishibashi H. Chem. Pharm. Bull.  1998,  46:  860 
    Google Scholar
  • 3h Matsumoto K. Suzuki M. Yoneda N. Miyoshi M. Synthesis  1976,  805 
    Google Scholar
  • 3i Possel O. Van Leusen A. Heterocycles  1977,  7:  77 
    Google Scholar
  • 3j van Leusen AM. Hoogenboom BE. Siderius H. Tetrahedron Lett.  1972,  13:  2369 
    Google Scholar
  • For reviews, see:
  • 4a Welton T. Chem. Rev.  1999,  99:  2071 
    Google Scholar
  • 4b Wasserscheid P. Keim W. Angew. Chem. Int. Ed.  2000,  39:  3772 
    Google Scholar
  • 4c Parvulescu VI. Hardacre C. Chem. Rev.  2007,  107:  2615 
    Google Scholar
  • 4d van Rantwijk F. Sheldon RA. Chem. Rev.  2007,  107:  2757 
    Google Scholar
  • 4e Martins MAP. Frizzo CP. Moreira DN. Zanatta N. Bonacorso HG. Chem. Rev.  2008,  108:  2015 
    Google Scholar
  • 4f de Maria PD. Angew. Chem. Int. Ed.  2008,  47:  2 
    Google Scholar
  • 6 van Leusen AM. Boerma GJM. Helmholdt RB. Siderius H. Strating J. Tetrahedron Lett.  1972,  2367 
    CrossrefGoogle Scholar
  • 7 Sisko J. Mellinger M. Sheldrake PW. Baine NH. Tetrahedron Lett.  1996,  37:  8113 
    CrossrefGoogle Scholar
  • 8 van Leusen AM. Bouma RJ. Possel O. Tetrahedron Lett.  1975,  3487 
    CrossrefGoogle Scholar
5

Wu B., Zhang J., Zheng Z.-G., Yang M., Yu X.-Q.; Chin. J. Chem.; 2008, in press

9

Representative Preparation of Monosubstituted TosMIC: 1-Bromobutane (5a; 0.206 g, 1.5 mmol) was added to the mixture of TosMIC (4; 0.195 g, 1 mmol), K2CO3 (0.414 g, 3 mmol) and [bmim]Br (2.5 mL). After vigorous stirring for 12 h at r.t., the mixture was poured into H2O (10 mL), and was extracted with Et2O (3 × 10 mL). The combined organics were washed with H2O and brine. The organic phase was dried over Na2SO4, and concentrated in vacuum. The crude product was purified by chromatography on silica gel (PE-EtOAc, 4:1) to provide pure compound 2a (95%).

10

Representative Preparation of 4,5-Disubstituted Oxazoles: 1-Bromobutane (5a; 0.206 g, 1.5 mmol) was added to the mixture of TosMIC (4; 0.195 g, 1 mmol), K2CO3 (0.414 g, 3 mmol) and [bmim]Br (2.5 mL). After vigorous stirring 12 h at r.t., 4 was consumed, and benzaldehyde (6a; 0.127 g, 1.2 mmol) was added. After about 10 h of stirring, the mixture was poured into H2O (10 mL), and was extracted with Et2O (3 × 10 mL). The combined organics were washed with H2O and brine. The organic phase was dried over Na2SO4, and concentrated in vacuum. The crude product was purified by chromatography on silica gel (PE-EtOAc, 10:1) to provide pure compound 7a (85%).

11

Spectroscopic Data for Products:
Compound 2a: ¹H NMR (400 MHz, CDCl3): δ = 0.91-0.95 (t, J = 14.4 Hz, 3 H), 1.33-1.49 (m, 3 H), 1.56-1.65 (m, 1 H), 1.79-1.88 (m, 1 H), 2.15-2.21 (m, 1 H), 2.48 (s, 3 H), 4.43-4.46 (m, 1 H), 7.41-7.44 (d, J = 8.0 Hz, 2 H), 7.85-7.87 (d, J = 8.4 Hz, 2 H). ¹³C NMR (100 MHz, CDCl3): δ = 13.7, 21.8, 21.8, 27.4, 28.2, 73.0, 130.1, 130.2, 131.2, 146.6, 164.9.
Compound 2b: ¹H NMR (400 MHz, CDCl3): δ = 1.74-1.75 (d, J = 6.8 Hz, 3 H), 2.50 (s, 3 H), 4.60-4.65 (m, 1 H), 7.44-7.46 (d, J = 8.0 Hz, 2 H), 7.87-7.89 (d, J = 8.0 Hz, 2 H). ¹³C NMR (100 MHz, CDCl3): δ = 15.5, 21.8, 68.3, 130.2, 130.7, 146.7, 164.6.
Compound 2c: ¹H NMR (400 MHz, CDCl3): δ = 1.16-1.19 (t, J = 15.2 Hz, 3 H), 1.84-1.92 (m, 1 H), 2.23-2.29 (m, 1 H), 2.49 (s, 3 H), 4.38-4.42 (m, 1 H), 7.42-7.44 (d, J = 8.0 Hz, 2 H), 7.86-7.88 (d, J = 8.4 Hz, 2 H). ¹³C NMR (100 MHz, CDCl3): δ = 9.9, 21.8, 22.5, 74.2, 130.0, 130.2, 131.3, 146.6, 164.9.
Compound 2d: ¹H NMR (400 MHz, CDCl3): δ = 0.86-0.90 (t, J = 13.6 Hz, 3 H), 1.27-1.37 (m, 10 H), 1.40-1.48 (m,
1 H), 1.58-1.65 (m, 1 H), 1.78-1.88 (m, 1 H), 2.14-2.22 (m, 1 H), 2.49 (s, 3 H), 4.43-4.47 (m, 1 H), 7.42-7.44 (d, J = 8.0 Hz, 2 H), 7.86-7.88 (d, J = 8.4 Hz, 2 H). ¹³C NMR (100 MHz, CDCl3): δ = 14.3, 22.0, 22.8, 25.6, 28.6, 28.8, 29.2, 29.3, 31.9, 73.2, 130.3, 130.3, 131.4, 146.7, 165.1.
Compound 2e: ¹H NMR (400 MHz, CDCl3): δ = 2.49 (s, 3 H), 2.96-3.02 (m, 1 H), 3.58-3.62 (m, 1 H), 4.58-4.61 (m, 1 H), 7.26-7.27 (m, 2 H), 7.29-7.37 (m, 3 H), 7.43-7.45 (d, J = 8.0 Hz, 2 H), 7.90-7.92 (d, J = 8.4 Hz, 2 H). ¹³C NMR (100 MHz, CDCl3): δ = 21.8, 34.8, 74.2, 128.1, 129.1, 129.3, 130.2, 130.2, 131.2, 133.3, 146.8, 166.0.
Compound 2f: ¹H NMR (400 MHz, CDCl3): δ = 2.49 (s,
3 H), 2.53-2.61 (m, 1 H), 2.95 (s, 1 H), 4.47-4.51 (m, 1 H), 5.28-5.33 (m, 2 H), 5.73-5.83 (m, 1 H), 7.43-7.45 (d, J = 8.0 Hz, 2 H), 7.87-7.89 (d, J = 8.4 Hz, 2 H). ¹³C NMR (100 MHz, CDCl3): δ = 21.8, 21.8, 29.7, 33.1, 72.3, 121.3, 121.4, 129.3, 130.2, 131.1, 146.7, 165.5.
Compound 2g: ¹H NMR (400 MHz, CDCl3): δ = 1.16-1.18 (d, J = 6.8 Hz, 3 H), 1.21-1.22 (d, J = 6.4 Hz, 3 H), 2.48 (s, 3 H), 2.70-2.77 (m, 1 H), 4.33-4.34 (d, J = 3.6 Hz, 1 H), 7.41-7.43 (d, J = 8.0 Hz, 2 H), 7.86-7.88 (d, J = 8.0 Hz, 2 H). ¹³C NMR (100 MHz, CDCl3): δ = 16.9, 20.8, 27.9, 30.9, 78.0, 129.6, 130.2, 133.0, 146.4, 165.5.
Compound 7a: ¹H NMR (400 MHz, CDCl3): δ = 0.93-0.97 (t, J = 14.8 Hz, 3 H), 1.38-1.48 (m, 2 H), 1.69-1.77 (m, 2 H), 2.75-2.79 (t, J = 15.6 Hz, 2 H), 7.31-7.35 (t, J = 14.8 Hz,
1 H), 7.42-7.46 (t, J = 15.2 Hz, 2 H), 7.59-7.61 (d, J = 8.8 Hz, 2 H), 7.83 (s, 1 H). ¹³C NMR (100 MHz, CDCl3): δ = 13.9, 22.5, 26.7, 30.8, 125.6, 127.8, 128.7, 129.0, 135.8, 145.3, 149.1. GC-MS (ES): m/z = 201 [M]+.
Compound 7b: ¹H NMR (400 MHz, CDCl3): δ = 0.92-0.96 (m, 3 H), 1.37-1.46 (m, 2 H), 1.68-1.75 (m, 2 H), 2.71-2.75 (t, J = 15.2 Hz, 2 H), 3.84 (s, 3 H), 6.96-6.98 (m, 2 H), 7.51-7.53 (m, 2 H), 7.80 (s, 1 H). ¹³C NMR (100 MHz, CDCl3):
δ = 13.9, 22.5, 26.6, 30.9, 55.3, 114.3, 121.7, 130.1, 130.1, 134.4, 145.4, 148.7, 159.3. GC-MS (ES): m/z = 231 [M]+.
Compound 7c: ¹H NMR (400 MHz, CDCl3): δ = 0.92-0.96 (t, J = 14.8 Hz, 3 H), 1.37-1.47 (m, 2 H), 1.68-1.76 (m, 2 H), 2.38 (s, 3 H), 2.73-2.77 (t, J = 15.2 Hz, 2 H), 7.23-7.25 (d, J = 8.0 Hz, 2 H), 7.48-7.50 (d, J = 8.0 Hz, 2 H), 7.81 (s, 1 H). ¹³C NMR (100 MHz, CDCl3): δ = 13.9, 21.2, 22.5, 26.7, 30.9, 125.7, 126.2, 129.5, 135.2, 137.8, 145.5, 148.9. GC-MS (ES): m/z = 215 [M]+.
Compound 7d: ¹H NMR (400 MHz, CDCl3): δ = 0.92-0.96 (t, J = 14.8 Hz, 3 H), 1.36-1.46 (m, 2 H), 1.67-1.75 (m, 2 H), 2.71-2.74 (t, J = 15.2 Hz, 2 H), 7.10-7.16 (m, 2 H), 7.53-7.58 (m, 2 H), 7.81 (s, 1 H). ¹³C NMR (100 MHz, CDCl3):
δ = 13.9, 22.5, 26.6, 30.8, 115.8, 116.0, 125.2, 125.2, 127.5, 135.5, 135.5, 144.6, 149.1, 161.0, 163.5. GC-MS (ES): m/z = 219 [M]+.
Compound 7e: ¹H NMR (400 MHz, CDCl3): δ = 0.93-0.96 (t, J = 14.8 Hz, 3 H), 1.39-1.44 (m, 2 H), 1.68-1.74 (m, 2 H), 2.72-2.76 (t, J = 5.6 Hz, 2 H), 7.45-7.47 (d, J = 8.8 Hz, 2 H), 7.56-7.58 (d, J = 8.4 Hz, 2 H), 7.84 (s, 1 H). ¹³C NMR (100 MHz, CDCl3): δ = 13.9, 22.5, 26.7, 30.7, 121.8, 127.1, 127.9, 128.1, 132.0, 136.4, 144.4, 149.3. GC-MS (ES):
m/z = 279 [M]+.
Compound 7f: ¹H NMR (400 MHz, CDCl3): δ = 0.85-0.89 (t, J = 14.4 Hz, 3 H), 1.29-1.35 (m, 2 H), 1.61-1.67 (m, 2 H), 2.51-2.55 (t, J = 15.2 Hz, 2 H), 7.33-7.39 (m, 3 H), 7.49-7.51 (m, 1 H), 7.91 (s, 1 H). ¹³C NMR (100 MHz, CDCl3):
δ = 13.8, 22.3, 25.7, 30.6, 126.7, 127.9, 130.2, 130.5, 131.8, 134.2, 137.9, 143.4, 150.2. GC-MS (ES): m/z = 235 [M]+.
Compound 7g: ¹H NMR (400 MHz, CDCl3): δ = 0.94-0.97 (t, J = 14.8 Hz, 3 H), 1.38-1.47 (m, 2 H), 1.69-1.77 (m, 2 H), 2.75-2.78 (t, J = 15.2 Hz, 2 H), 7.29-7.31 (m, 1 H), 7.35-7.39 (t, J = 15.6 Hz, 1 H), 7.46-7.49 (m, 1 H), 7.59-7.60 (t, J = 3.6 Hz, 1 H), 7.84 (s, 1 H). ¹³C NMR (100 MHz, CDCl3): δ = 13.4, 22.5, 26.7, 30.7, 123.6, 125.6, 127.8, 130.0, 130.6, 134.8, 136.9, 144.1, 149.4. GC-MS (ES): m/z = 235 [M]+.
Compound 7h: ¹H NMR (400 MHz, CDCl3): δ = 0.93-0.96 (t, J = 14.8 Hz, 3 H), 1.39-1.45 (m, 2 H), 1.68-1.76 (m, 2 H), 2.72-2.76 (t, J = 15.2 Hz, 2 H), 7.39-7.42 (m, 2 H), 7.51-7.53 (m, 2 H), 7.83 (s, 1 H). ¹³C NMR (100 MHz, CDCl3):
δ = 13.9, 22.5, 26.7, 30.7, 126.8, 127.4, 129.0, 129.4, 129.4, 133.7, 136.3, 144.4, 149.2. GC-MS (ES): m/z = 235 [M]+.
Compound 7i: ¹H NMR (400 MHz, CDCl3): δ = 0.95-0.99 (t, J = 14.8 Hz, 3 H), 1.42-1.48 (m, 2 H), 1.72-1.78 (m, 2 H), 2.82-2.86 (t, J = 15.6 Hz, 2 H), 7.77-7.79 (m, 2 H), 7.93 (s, 1 H), 8.30-8.32 (m, 2 H). ¹³C NMR (100 MHz, CDCl3): δ = 13.9, 22.5, 27.1, 30.6, 124.3, 125.7, 128.1, 129.8, 134.9, 139.6, 143.5, 146.7, 150.3. GC-MS (ES): m/z = 246 [M]+.
Compound 7j: ¹H NMR (400 MHz, CDCl3): δ = 0.82-0.86 (t, J = 14.8 Hz, 3 H), 1.26-1.35 (m, 2 H), 1.63-1.71 (m, 2 H), 2.55-2.59 (t, J = 15.6 Hz, 2 H), 7.50-7.56 (m, 4 H), 7.83-7.85 (m, 1 H), 7.89-7.95 (m, 2 H), 8.00 (s, 1 H). ¹³C NMR (100 MHz, CDCl3): δ = 13.8, 22.4, 25.9, 31.0, 125.1, 125.5, 126.0, 126.3, 126.7, 128.4, 128.5, 129.8, 131.9, 133.8, 137.8, 145.2, 150.2. GC-MS (ES): m/z = 251 [M]+.
Compound 7k: ¹H NMR (400 MHz, CDCl3): δ = 0.93-0.97 (t, J = 14.8 Hz, 3 H), 1.34-1.43 (m, 2 H), 1.63-1.71 (m, 2 H), 2.60-2.63 (t, J = 4.8 Hz, 2 H), 6.85-6.89 (d, J = 16.4 Hz,
1 H), 6.99-7.03 (d, J = 16.4 Hz, 1 H), 7.26-7.29 (t, J = 12.0 Hz, 1 H), 7.34-7.38 (t, J = 15.2 Hz, 2 H), 7.47-7.49 (d, J = 7.6 Hz, 2 H), 7.77 (s, 1 H). ¹³C NMR (100 MHz, CDCl3):
δ = 13.8, 13.9, 22.3, 31.0, 31.1, 112.5, 112.5, 126.4, 128.0, 128.0, 128.3, 128.4, 128.8, 128.8, 136.7, 136.7, 137.7, 145.1, 149.4, 149.4. GC-MS (ES): m/z = 227 [M]+.
Compound 7l: ¹H NMR (400 MHz, CDCl3): δ = 0.90-0.94 (t, J = 14.4 Hz, 3 H), 1.33-1.43 (m, 2 H), 1.64-1.71 (m, 2 H), 2.75-2.79 (t, J = 15.2 Hz, 2 H), 6.47-6.48 (m, 1 H), 6.54-6.54 (d, J = 3.2 Hz, 1 H), 7.47 (s, 1 H), 7.76 (s, 1 H). ¹³C NMR (100 MHz, CDCl3): δ = 13.8, 22.3, 25.8, 30.8, 107.1, 111.3, 136.0, 138.6, 142.4, 149.0. GC-MS (ES): m/z = 191 [M]+.
Compound 7m: ¹H NMR (400 MHz, CDCl3): δ = 0.87-0.93 (m, 9 H), 1.28-1.34 (m, 2 H), 1.53-1.59 (m, 2 H), 1.88-1.95 (m, 1 H), 2.37-2.43 (m, 4 H), 7.65 (s, 1 H). ¹³C NMR (100 MHz, CDCl3): δ = 13.9, 22.3, 22.4, 25.3, 28.1, 31.2, 33.5, 135.0, 146.5, 148.9. GC-MS (ES): m/z = 181 [M]+.
Compound 7n: ¹H NMR (400 MHz, CDCl3): δ = 0.89-0.92 (t, J = 14.4 Hz, 3 H), 1.26-1.35 (m, 6 H), 1.50-1.59 (m, 4 H), 1.70-1.83 (m, 4 H), 2.42-2.49 (m, 2 H), 2.60-2.66 (m, 1 H), 7.64 (s, 1 H). ¹³C NMR (100 MHz, CDCl3): δ = 13.9, 22.3, 25.3, 25.8, 26.3, 31.5, 31.7, 34.8, 132.7, 148.5, 151.1. GC-MS (ES): m/z = 207 [M]+.
Compound 7o: ¹H NMR (400 MHz, CDCl3): δ = 1.31-1.35 (t, J = 15.2 Hz, 3 H), 2.78-2.84 (m, 2 H), 7.32-7.35 (t, J = 14.8 Hz, 1 H), 7.41-7.46 (m, 2 H), 7.59-7.61 (d, J = 7.6 Hz, 2 H), 7.84 (s, 1 H). ¹³C NMR (100 MHz, CDCl3): δ = 13.1, 20.3, 125.7, 127.9, 128.8, 128.9, 136.9, 145.1, 149.2. GC-MS (ES): m/z = 173 [M]+.
Compound 7p: ¹H NMR (400 MHz, CDCl3): δ = 4.15 (s,
2 H), 7.19-7.28 (m, 4 H), 7.30-7.35 (m, 2 H), 7.40-7.43 (m, 2 H), 7.59-7.62 (m, 2 H), 7.87 (s, 1 H). ¹³C NMR (100 MHz, CDCl3): δ = 32.9, 125.9, 126.5, 128.3, 125.5, 128.5, 128.6, 128.9, 133.9, 138.6, 146.6, 149.5. GC-MS (ES): m/z = 235 [M]+.
Compound 7q: ¹H NMR (400 MHz, CDCl3): δ = 0.89-0.92 (t, J = 14.8 Hz, 3 H), 1.58-1.67 (m, 2 H), 2.55-2.59 (t, J = 14.8 Hz, 2 H), 3.82 (s, 1 H), 7.11-7.22 (m, 4 H), 7.24-7.30 (m, 1 H), 7.70 (s, 2H). ¹³C NMR (100 MHz, CDCl3): δ = 13.6, 21.6, 26.5, 32.1, 126.3, 128.5, 128.6, 133.2, 139.3, 148.0, 149.1. GC-MS (ES): m/z = 235 [M]+.
Compound 7r: ¹H NMR (400 MHz, CDCl3): δ = 3.53-3.54 (d, J = 6.0 Hz, 2 H), 5.12-5.14 (m, 1 H), 5.17 (s, 1 H), 6.00-6.10 (m, 1 H), 7.30-7.34 (t, J = 14.4 Hz, 1 H), 7.40-7.44 (t, J = 15.2 Hz, 2 H), 7.58-7.60 (d, J = 8.0 Hz, 2 H), 7.84 (s,
1 H). ¹³C NMR (100 MHz, CDCl3): δ = 31.4, 116.6, 125.8, 128.2, 128.6, 128.8, 133.1, 134.4, 146.2, 149.4. GC-MS (ES): m/z = 185 [M]+.
Compound 7s: ¹H NMR (400 MHz, CDCl3): δ = 0.85-0.88 (t, J = 13.6 Hz, 3 H), 1.27 (s, 6 H), 1.55-1.60 (m, 2 H), 2.57-2.61 (t, J = 14.8 Hz, 2 H), 3.21-3.23 (d, J = 6.4 Hz, 2 H), 5.05-5.11 (m, 2 H), 5.87-5.96 (m, 1 H), 7.69 (s, 1 H). ¹³C NMR (100 MHz, CDCl3): δ = 14.0, 22.5, 24.4, 28.1, 28.7, 30.2, 31.4, 116.0, 131.9, 135.2, 147.9, 148.9. GC-MS (ES): m/z = 193 [M]+.
Compound 7t: ¹H NMR (400 MHz, CDCl3): δ = 1.32-1.34 (t, J = 6.8 Hz, 6 H), 3.23-3.30 (m, 1 H), 7.32-7.36 (t, J = 15.2 Hz, 1 H), 7.43-7.46 (t, J = 15.2 Hz, 2 H), 7.57-7.60 (t, J = 8.4 Hz, 2 H) 7.84 (s, 1 H). ¹³C NMR (100 MHz, CDCl3): δ = 22.0, 25.7, 126.1, 128.0, 128.8, 129.0, 140.9, 144.2, 149.4. GC-MS (ES): m/z = 187 [M]+.
Compound 8a: ¹H NMR (400 MHz, CDCl3): δ = 0.90-0.94 (t, J = 14.8 Hz, 6 H), 1.29-1.36 (m, 4 H), 1.38-1.46 (m, 2 H), 1.49-1.55 (m, 2 H), 1.88-2.05 (m, 4 H), 2.48 (s, 3 H), 7.40-7.42 (d, J = 8.0 Hz, 2 H), 7.85-7.87 (d, J = 8.4 Hz, 2 H).